ASCO Genitourinary Cancers Symposium (Statin use & outcomes.)

[pjoshea13]

"In a post-hoc analysis of two prospective randomized clinical trials statin use was associated with superior OS {overall survival} in mCPRC pts treated with P or AA/P." {prednisone (P), abiraterone (AA)}

-Patrick

230 Poster Session (Board #L6), Thu, 11:30 AM-1:00 PM and

5:15 PM-6:15 PM

Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.

Guillermo de Velasco, David Lora, David Lorente, Toni K. Choueiri, Christopher Sweeney, Daniel E. Castellano; Hospital 12 de Octubre, Madrid, Spain; Servicio Oncologia Medica Hospital Universitario La Fe, Valencia, Spain; Dana-Farber Cancer Institute/ Brigham and Women’s Hospital/ Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

Background: Retrospective database studies have suggested that statins may have a positive impact on some mCRPC pts treated with prednisone (P)/abiraterone (AA)

Methods: We conducted a post-hoc analysis of individual pt data of mCRPC pts treated with AA and/or P on randomized phase III clinical trials COU -AA-301 and COU-AA-302 to analyze the impact of statins on overall survival (OS). Statistical analyses were performed using the Kaplan Meier method and Cox regression adjusted for known prognostic factors. This study, was carried out under YODA Project #2016-1136

Results: 458 (41%) prechemotherapy pts and 348 (29%) postchemotherapy pts were statins users (Table). Improved OS was observed for mCPRC pts who were statins users in the postdocetaxel setting [HR: 0.82 (95% CI: 0.71 to 0.94); p = 0.006], and there was a trend towards a prolonged OS in the predocetaxel setting [HR: 0.89 (95% CI: 0.77 to 1.03); p = 0.13] adjusted by interventional treatment (AA and/or P). In the predocetaxel setting there were no significant differences in OS between the groups AA/P/non-statin users and placebo/P/statin users (p=0.3). In the multivariate analysis, patients randomized to AA/P who were statins users and presenting ECOG ,2 had superior OS in the postdocetaxel setting. Similarly, age, ECOG and statin use were the strongest prognostic factors in the predocetaxel setting.

Conclusions: In a post-hoc analysis of two prospective randomized clinical trials statin use was associated with superior OS in mCPRC pts treated with P or AA/P. Further studies are needed to confirm these results and guide use of statins as adjunct to P and A.

{Table would not copy. See: gucasym.org/sites/gucasym.o...